Sand Grove Capital Management’s Amedisys AMED Stock Holding History

Sand Grove Capital Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-308,254	Closed	-$30.3M	–	13
2025 Q2	$30.3M	Buy	308,254 +112,577	+58%	+$10.7M	15.27%	1
2025 Q1	$18.1M	Buy	+195,677	New	+$18M	15.02%	4
2024 Q4	–	Sell	-340,056	Closed	-$32.8M	–	15
2024 Q3	$32.8M	Sell	340,056 -95,010	-22%	-$9.27M	12.82%	1
2024 Q2	$39.9M	Buy	435,066 +188,475	+76%	+$17.5M	11.68%	3
2024 Q1	$22.7M	Buy	246,591 +131,959	+115%	+$12.4M	5.2%	7
2023 Q4	$10.9M	Sell	114,632 -168,218	-59%	-$15.7M	2.9%	12
2023 Q3	$26.4M	Buy	+282,850	New	+$26.1M	3.29%	11

Other funds holding AMED

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

MCI

MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Sand Grove Capital Management's AMED Position: Q3 2025 in Review

Sand Grove Capital Management sold out of Amedisys (AMED) in Q3 2025, closing a stake of 308,254 shares — an estimated $30.3M sold.

Sand Grove Capital Management first reported a position in AMED in Q3 2023 and held it in 7 quarters. The position peaked at $39.9M in Q2 2024. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

Sand Grove Capital Management reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
Sand Grove Capital Management sold 308,254 Amedisys shares in Q3 2025, an estimated $30.3M.
Sand Grove Capital Management first reported a position in Amedisys in Q3 2023 and held it in 7 quarters.
Sand Grove Capital Management's Amedisys position peaked at $39.9M in Q2 2024.
4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Sand Grove Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.